MRVI Maravai Lifesciences Holdings Inc

Price (delayed)

$8.94

Market cap

$2.25B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.99

Enterprise value

$2.25B

Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are ...

Highlights
Maravai Lifesciences Holdings's quick ratio has surged by 85% YoY and by 41% QoQ
MRVI's net income has dropped by 185% year-on-year and by 10% since the previous quarter
Maravai Lifesciences Holdings's EPS has plunged by 185% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of MRVI
Market
Shares outstanding
251.92M
Market cap
$2.25B
Enterprise value
$2.25B
Valuations
Price to book (P/B)
5.47
Price to sales (P/S)
4.32
EV/EBIT
3.34
EV/EBITDA
3.1
EV/Sales
8.19
Earnings
Revenue
$274.1M
EBIT
$673.44M
EBITDA
$725.07M
Free cash flow
-$24.25M
Per share
EPS
-$0.99
Free cash flow per share
-$0.18
Book value per share
$1.63
Revenue per share
$2.07
TBVPS
$6.83
Balance sheet
Total assets
$1.44B
Total liabilities
$667.25M
Debt
$555.72M
Equity
$410.66M
Working capital
$608.86M
Liquidity
Debt to equity
1.35
Current ratio
11.32
Quick ratio
10.14
Net debt/EBITDA
-0.01
Margins
EBITDA margin
264.5%
Gross margin
44%
Net margin
-47.8%
Operating margin
-20.6%
Efficiency
Return on assets
-7%
Return on equity
-28.1%
Return on invested capital
55%
Return on capital employed
48.6%
Return on sales
245.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRVI stock price

How has the Maravai Lifesciences Holdings stock price performed over time
Intraday
3.95%
1 week
27.9%
1 month
13.45%
1 year
-28.59%
YTD
36.49%
QTD
24.86%

Financial performance

How have Maravai Lifesciences Holdings's revenue and profit performed over time
Revenue
$274.1M
Gross profit
$120.7M
Operating income
-$56.33M
Net income
-$131.04M
Gross margin
44%
Net margin
-47.8%
MRVI's net income has dropped by 185% year-on-year and by 10% since the previous quarter
The operating margin has plunged by 137% YoY and by 70% from the previous quarter
The operating income has dropped by 114% year-on-year and by 61% since the previous quarter
Maravai Lifesciences Holdings's gross profit has shrunk by 78% YoY and by 14% QoQ

Growth

What is Maravai Lifesciences Holdings's growth rate over time

Valuation

What is Maravai Lifesciences Holdings stock price valuation
P/E
N/A
P/B
5.47
P/S
4.32
EV/EBIT
3.34
EV/EBITDA
3.1
EV/Sales
8.19
Maravai Lifesciences Holdings's EPS has plunged by 185% YoY and by 10% from the previous quarter
The company's equity fell by 21% YoY
MRVI's price to book (P/B) is 9% more than its last 4 quarters average of 5.0
Maravai Lifesciences Holdings's revenue has plunged by 62% YoY and by 5% from the previous quarter
The price to sales (P/S) is 31% more than the last 4 quarters average of 3.3

Efficiency

How efficient is Maravai Lifesciences Holdings business performance
The return on equity has dropped by 193% year-on-year and by 17% since the previous quarter
The return on assets has declined by 23% since the previous quarter
The company's return on invested capital rose by 12% QoQ
Maravai Lifesciences Holdings's ROS has increased by 3.9% from the previous quarter

Dividends

What is MRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRVI.

Financial health

How did Maravai Lifesciences Holdings financials performed over time
MRVI's total assets is 117% greater than its total liabilities
Maravai Lifesciences Holdings's quick ratio has surged by 85% YoY and by 41% QoQ
Maravai Lifesciences Holdings's current ratio has soared by 85% YoY and by 42% from the previous quarter
The company's debt is 35% higher than its equity
Maravai Lifesciences Holdings's debt to equity has increased by 30% YoY
The company's equity fell by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.